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Abstract
Background: The aging gene p66Shc, is an important mediator of oxidative stress-induced vascular dysfunction and disease.
In cultured human aortic endothelial cells (HAEC), p66Shc deletion increases endothelial nitric oxide synthase (eNOS)
expression and nitric oxide (NO) bioavailability via protein kinase B. However, the putative role of the NO pathway on p66Shc
activation remains unclear. This study was designed to elucidate the regulatory role of the eNOS/NO pathway on p66Shc
activation.
Methods and Results: Incubation of HAEC with oxidized low density lipoprotein (oxLDL) led to phosphorylation of p66Shc at
Ser-36, resulting in an enhanced production of superoxide anion (O2
-). In the absence of oxLDL, inhibition of eNOS by small
interfering RNA or L-NAME, induced p66Shc phosphorylation, suggesting that basal NO production inhibits O2
- production.
oxLDL-induced, p66Shc-mediated O2- was prevented by eNOS inhibition, suggesting that when cells are stimulated with
oxLDL eNOS is a source of reactive oxygen species. Endogenous or exogenous NO donors, prevented p66Shc activation and
reduced O2- production. Treatment with tetrahydrobiopterin, an eNOS cofactor, restored eNOS uncoupling, prevented
p66Shc activation, and reduced O2- generation. However, late treatment with tetrahydropterin did not yield the same result
suggesting that eNOS uncoupling is the primary source of reactive oxygen species.
Conclusions: The present study reports that in primary cultured HAEC treated with oxLDL, p66Shc-mediated oxidative stress
is derived from eNOS uncoupling. This finding contributes novel information on the mechanisms of p66Shc activation and its
dual interaction with eNOS underscoring the importance eNOS uncoupling as a putative antioxidant therapeutical target in
endothelial dysfunction as observed in cardiovascular disease.
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Introduction
Endothelial nitric oxide synthase (eNOS) produces nitric oxide
(NO), a key factor involved in maintaining endothelial homeostasis
[1]. Further, NO plays a key role in preventing endothelial
dysfunction by scavenging O2- [2], reducing adhesion of platelets
and leukocytes [3], and inhibiting migration and proliferation of
smooth muscle cells [4]. However, under pathological conditions
eNOS can become a source of reactive oxygen species [5,6,7]. The
underlying mechanisms of this switch include oxidization of
tetrahydrobiopterin [5], depletion of tetrahydrobiopterin [8], and
dephosphorylation of eNOS at Thr495 [9].
The p66Shc adaptor protein is an important mediator of
oxidative stress-induced vascular dysfunction [10], acting as a
redox enzyme implicated in mitochondrial ROS generation and
the translation of oxidative signals into apoptosis [11,12,13,14,15].
Genetic deletion of p66Shc in the mouse extends lifespan by
reducing the production of intracellular oxidants [16] and in
ApoE2/2 mice treated with high fat diet limits atherosclerotic
plaque formation due to decreased lipid peroxidation [17].
Previous studies reported that in human aortic endothelial cells
oxidized LDL increases ROS production via phosphorylation of
the p66Shc protein at ser36 through the lectin-like oxLDL
receptor-1, activation of protein kinase C beta-2, and c-Jun N-
terminal kinase [18]; of note, this effect can be prevented by
p66Shc silencing. These results underscored the critical role of
p66Shc in oxLDL-induced oxidative stress in endothelial cells [18].
Indeed, activation of p66Shc leads to a surge of reactive oxygen
species from mitochondria [16,19] and/or via NADPH oxidase
[18,20].
Further, it has been reported that p66Shc overexpression inhibits
eNOS-dependent NO production [21], while deletion of p66Shc
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leads to increased phosphorylation of eNOS at the activatory
phosphorylation site Ser1177 through the protein kinase B
pathway [22]. These findings imply an important role of p66Shc
adaptor protein in modulating endothelium-derived NO produc-
tion [22]. On the other hand, the role of endothelium-derived NO
in controlling p66Shc activation remained not known. The present
study was therefore designed to study the effects of eNOS, as well
as NO, on the expression of the p66Shc adaptor protein.
Materials and Methods
Cell culture experiments
Primary human aortic endothelial cells (HAEC; Clonetics,
Allschwil, Switzerland), from passage 4 to 6, were used. The cells
were cultured and passaged in EBM-2 medium supplied with
EGM-2 bulletkit (Clonetics, Walkersville USA). Experiments were
performed in EBM medium with 0.5% FBS. Cells were harvested
for further measurements (Western blotting, superoxide produc-
tion measurement) either within 60 minutes or after 24 hours of
exposure to oxLDL. NO donors or inhibitors were added to
medium 60 minutes before exposure of the cells to oxLDL.
Tetrahydrobiopterin was added to the medium 60 minutes prior
to (Before, B), 45 minutes (After Early, AE) or 16 hours (After
Later, AL) after the oxLDL stimulation.
Materials
Apocynin was purchased from SAFC (Saint. Louis, MO, USA).
8-Bromoguanosine 39,59-cyclic monophosphate, bradykinin, cal-
cium ionophore (A23187), N (G)-nitro-L- arginine methyl ester (L-
NAME), ODQ, tetrahydrobiopterin, siRNA against eNOS and N-
TER Nanoparticle siRNA Transfection system, and anti-a-tubulin
antibody were obtained from Sigma (Saint Louis, MO, USA).
Anti-Shc/p66 (pSer36) antibody was purchased from Calbiochem
(Darmstadt, Germany). DETA NONOate, DEA NONOate, and
KT5823 were purchased from Cayman (Michigan, USA).
Oxidized LDL and LDL are bought from Biomedical Technol-
ogies (Stoughton, MA, USA). Anti-Shc antibody was purchased
from Cell Signaling (Danvers, MA, USA). Anti-eNOS antibody
was bought from B&D transduction laboratories (NJ, USA). Anti-
rabbit and Anti-mouse second antibodies were bought from GE
healthcare (Buckinghamshire, UK).
Measurement of reactive oxygen species
O2
- generation in intact cells was assessed using the spin trap 1-
hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine (CMH).
Human aortic endothelial cells were collected in Krebs-HEPES
solution containing diethyldithiocarbonic acid sodium salt (DETC
5 uM), deferoxamine (25 uM), and CMH (200 mM). The formation
of the stable spin label 3-methoxycarbonyl-proxyl (CM’) was
determined at room temperature with an EMX ESR spectrometer
(Bruker, Bremen Germany).
Western blotting
Protein expression was determined by Western blot analysis.
Samples from cell culture were collected in lysis buffer (NaCl
150 mM, EDTA 1 mM, NaF 1 mM, DTT 1 mM, aprotinin
10 mg/ml, leupeptin 10 mg/ml, Na3VO4 0.1 mM, PMSF 1 mM,
and NP-40 0.5%). Proteins were loaded on a separating gel (SDS-
PAGE) and transferred to a polyvinylidene fluoride membrane by
semidry transfer. The membranes were incubated with antibody.
Related signals were quantified using a Scion image software
(Scion Corporation, Frederick, Maryland, USA).
Small interfering RNA (siRNA)
In certain experiments, predesigned small interfering RNA
(siRNA) against eNOS (59-CCUACAUCUGCAACCA-
CAU[dT][dT]-39; 10 nM) (Sigma, Saint Louis, MO, USA) were
applied. HAEC were transfected with siRNA against eNOS at
final concentration of 10 nM in a serum-free medium using N-
TER Nanoparticle siRNA Transfection System (NFS, Sigma,
Saint Louis, MO, USA), according to the manufacture’s protocol.
Cells were incubated with siRNA in serum-free and antibiotics-
free medium for four hours, followed by normal growth medium
for another 24 hours prior to the experiments. Nanoparticle
Formation Solution (NFS) and scrambled siGAPDH (59-
GGUUUACAUGUUCCAAUAU[dT][dT]-39; 10 nM) were
used as negative controls.
Data analysis
Data are presented as means6SEM, Statistical analysis was
performed by one–way ANOVA followed by a post hoc
comparison using the Bonferroni test (Prism, GraphPad Software,
San Diego, CA, USA). Differences were considered to indicate
statistically significant when the P value was less than 0.05.
Results
1. oxLDL induces p66Shc adaptor protein
phosphorylation and eNOS uncoupling
In HAEC, incubation with oxLDL (10 mg/ml) induced a
transient phosphorylation of p66Shc at the Ser-36 amino acid
residue. Nonetheless, total protein levels of p66Shc, as well as that
of the other two isoforms of the Shc adaptor protein family, p52Shc
and p46Shc, did not change within 60 minutes. In parallel, oxLDL
transiently reduced the dimer/monomor ratio of eNOS within
60 minutes (Figure 1 A, B, and C).
In line with our previous findings [18], phosphorylation of
p66Shc was also detectable after 24 hours of incubation of the cells
with oxLDL (10 mg/ml). After 24 hours, eNOS dimer/monomor
ratio was once again reduced, while compared to cells under
control condition or treated with native LDL (10 mg/ml), denoting
a biphasic response (Figure 1 D, E, and F).
2. eNOS plays a dual role for p66Shc phosphorylation
2.1 Inhibition of eNOS enhances p66Shc phosphorylation
under basal condition, but reduces p66Shc phosphorylation
under stimulated condition. After 24 hours of exposure to
oxLDL, p66Shc phosphorylation was increased in cells treated with
L-NAME or L-NAME combined with native LDL. However in
the presence of L-NAME, oxLDL-induced p66Shc phosphoryla-
tion was significantly reduced (Figure 2 A, B).
To further corroborate the findings with L-NAME treatment,
small interfering RNA against eNOS (Si-eNOS, Figure S1) were
used. In line with the pharmacologic inhibition of eNOS, siRNA
induced a significantly higher level of phosphorylated p66Shc
under quiescent condition. Furthermore, phosphorylation of
p66Shc was reduced when cells were exposed to both oxLDL
and Si-eNOS (Figure 2 C, D).
2.2 Activation of Nitric oxide pathway prevents p66Shc
phosphorylation. After 24 hours, DetaNO [23], a NO donor
with a half life of up to 20 hours, at 1 mM, but not at 0.1 mM,
significantly reduced oxLDL-induced p66Shc phosphorylation.
DeaNO [24], another NO donor which has a half life of
2 minutes, either at 1 mM or 0.1 mM, did not significantly
change the level of p66Shc phosphorylation (Figure 3). After
24 hours, bradykinin (1 mM) [25] or calcium ionphore (1 mM) [26]
eNOS and Oxidative Stress in Endothelial Cells
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significantly reduced oxLDL-induced p66Shc phosporylation (Fig-
ure 4).
8-Br-cGMP (1 mM) [27], an analogue of cyclic guanosine
monophosphate, prevented the oxLDL-induced p66Shc phosphor-
ylation after 24 hours stimulation of oxLDL (Figure S2).
2.3 Inhibition of protein kinase G pathway does not
change p66Shc phosphorylation. ODQ (10 mM) [28], an
inhibitor of soluble guanylyl cyclase, did not significantly change
the phosphorylation level of p66Shc protein, either in the presence
or absence of oxLDL. Likewise, KT5823 (1 mM) [29], an inhibitor
of protein kinase G, did not significantly alter the phosphorylation
level of the p66Shc protein, either in the presence or absence of
oxLDL (Figure S3).
3. Tetrahydrobiopterin prevents p66Shc phosphorylation
and restores eNOS uncoupling
After 24 h of exposure to oxLDL, tetrahydrobiopterin (10 mM)
[30], a cofactor of eNOS, increased the dimer/monomor ratio of
eNOS and prevented p66Shc phosphorylation. Furthermore,
apocynin, an antioxidant, significantly reduced the phosphoryla-
tion level of p66Shc, but did not change the dimer/monomor ratio
of eNOS (Figure 4).
Under the same experimental conditions, administration of
tetrahydrobiopterin (45 minutes after oxLDL), reduced p66Shc
phosphorylation, but did not change the eNOS dimer/monomor
ratio. Administration of tetradydrobiopterin (16 hours after
oxLDL), did not change the eNOS dimer/monomor ratio nor
oxLDL-induced p66Shc phosphorylation (Figure 5).
Figure 1. Representive Western blot (A, D) and densitometric quantification of eNOS uncoupling (B, E) and phospho-p66Shc protein
(C, F) expression in HAEC treated with oxLDL within sixty minutes (A, B, C) or for twenty four hours (D, E, F). eNOS uncoupling was
presented as ratio of dimer/monomer form of eNOS. The phosphorylation of p66Shc was normalized to total p66Shc protein and total p66Shc was
normalized to a-tubulin. Results are presented as means6SEM; n = 6. * p,0.05 vs. cells at 0 minutes or cells under control condition.
doi:10.1371/journal.pone.0107787.g001
eNOS and Oxidative Stress in Endothelial Cells
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e107787
4. oxLDL induces reactive oxygen species
The production of reactive oxygen species was measured in
HAEC 24 hours after exposure to oxLDL. In the presence of
oxLDL, but not native LDL, endothelial cells exhibited an
increased production of O2-. This enhanced production of O2-
was inhibited by apocynin (100 mM) [18]. In the absence of
oxLDL, L-NAME alone induced a high level of O2- in endothelial
cells, whereas in the presence of oxLDL, L-NAME significantly
reduced the production of O2
- (Figure 6).
Bradykinin or calcium ionophore significantly reduced oxLDL-
induced O2
- production. 8-Br-cGMP reduced the level of oxLDL-
induced O2
- (Figure 6).
Tetrahydrobiopterin, administrated either 60 minutes before
(B) or 45 minutes after oxLDL stimulation (AE), significantly
reduced oxLDL-induced O2
- production. However the late
administration (AL) failed to decrease O2
- production in endothe-
lial cell (Figure 6).
oxLDL did not change levels of protein peroxynitrition in
endothelial cells (Figure S4).
Discussion
This study analyzed the molecular mechanisms underlying the
dual role of eNOS and its product NO in controlling the activation
of p66Shc adaptor protein – an important mediator of ROS-
dependent cardiovascular disease. In primary HAECs, inhibition
of eNOS induced p66Shc activation and ROS production,
suggesting that under basal condition eNOS provides an inhibitory
signal preventing p66Shc activation and p66Shc-dependent ROS
production. In contrast, in primary HAECs stimulated by oxLDL,
eNOS uncoupled and acted as the primary source of p66Shc-
mediated ROS. Accordingly, under these conditions tetrahydro-
biopterin restored eNOS coupling and function, prevented p66Shc
activation, and reduced superoxide generation.
p66Shc adaptor protein is importantly involved in various forms
of cardiovascular disease by providing reactive oxygen species. Of
note, genetic deletion of p66Shc protein preserves endothelial
function in aging mice and extends life span of these animals.
Furthermore, p66Shc deletion preserves endothelial function and
reduces plaque formation in ApoE2/2 mice by virtue of a reduced
production of reactive oxygen species [16,17]. Similar effects occur
in diabetic endothelial dysfunction and in experimental stroke
[11,31].
p66Shc phosphorylation, at serine 36 amino acid residue,
mediates ROS production in different settings [16,18,32] via
activation of NADPH oxidase [18,20] and/or release of ROS
from mitochondria via opening of PTC pores [33].
Interestingly, in unstimulated HAECs, inhibition of eNOS by
the pharmacological inhibitor LNAME or by using siRNA
preventing translation of the protein, both induced p66Shc
phosphorylation and increased generation of O2-, suggesting that
under these conditions, basal release of NO inhibits the activation
of the adaptor protein and the formation of ROS, thereby playing
a so far unrecognized antioxidant role. Importantly, neither cyclic
Figure 2. Representive Western blot (A, C) and densitometric quantification of phospho-p66Shc protein expression (B, D) in HAEC
after twenty-four hours of incubation with oxLDL in the presence of nitric oxide synthase inhibitor (L-NAME 0.3 mM; A and B) and
in the presence of eNOS siRNA (10 nM, C and D). The phosphorylation of p66Shc was normalized to total p66Shc protein and total p66Shc was
normalized to a-tubulin. Results are presented as means6SEM; n = 8. * p,0.05 vs. cells under control conditions. # p,0.05 vs. oxLDL alone. (NFS:
nanoparticle formation solution).
doi:10.1371/journal.pone.0107787.g002
eNOS and Oxidative Stress in Endothelial Cells
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GMP nor protein kinase G is involved in this process since this
effect was not observed after treatment with ODQ or KT5823,
suggesting a direct interaction between O2
- and NO in the present
set up [2].
oxLDL, a key mediator of atherosclerosis, induced p66Shc
phosphorylation and in turn stimulated O2
- production in
endothelial cells, confirming that the adaptor protein p66Shc is
activated by the modified lipoprotein and a crucial regulator of
intracellular ROS generation [16,18]. In the presence of oxLDL,
the NO donor (DetaNO) as well as receptor-operated activators of
eNOS such as bradykinin or receptor-independent activators such
as calcium ionophore, reduced p66Shc activation and decreased
O2
- production. These results suggest that NO also provides a
protective effect against reactive oxygen species under stimulated
condition. Treatment with cyclic GMP prevented p66Shc phos-
phorylation and superoxide generation after 24 hours, indicating
that the protective role of basal NO is mediated through the NO-
cGMP pathway [1,34].
Of note, oxLDL transiently induced eNOS uncoupling and
p66Shc phosphorylation within 15 minutes of incubation. After
24 h of stimulation with oxLDL, inhibition of eNOS reduced
p66Shc phosphorylation and decreased the O2
- production
suggesting that under stimulated conditions eNOS becomes a
source of reactive oxygen species [5,35]. Apocynin reduced
oxLDL-induced p66Shc phosphorylation and superoxide produc-
tion, but did not restore eNOS uncoupling, indicating that eNOS
uncoupling is upstream of p66Shc activation. In line with that,
tetrahydrobiopterin, a cofactor of eNOS, restored oxLDL-induced
eNOS uncoupling and p66Shc-dependent superoxide generation,
once again suggesting that eNOS uncoupling is the primary source
of oxLDL-induced, p66Shc-mediated reactive oxygen species.
Uncoupling of eNOS is an important mechanism of endothelial
dysfunction in atherosclerosis [36], diabetes [37], and hyperten-
sion [5]. The underlying mechanisms of eNOS uncoupling include
tetrahydrobiopterin deficiency [38], decreased levels of L-arginine
[39], enhanced levels of asymmetric dimethylarginine [40] or S-
glutathionylation of eNOS [41]. Deficiency of tetrahydrobiopterin
seems to be the primary cause for eNOS uncoupling under
pathophysiological conditions [42]. Tetrahydrobiopterin facilitates
electron transfer from the eNOS reductase domain and maintains
the heme prosthetic group in its redox active forms. Further
tetrahydrobiopterin promotes and stabilizes eNOS protein mono-
mers into the active homodimeric form of the enzyme [38,43].
Increased levels of tetrahydrobiopterin enhance eNOS activity in
cultured cells [44,45] and promote vasodilatation in isolated
mouse pial arterioles [46]. In animal experiments, tetrahydro-
biopterin treatment reduces oxidative stress and preserves
endothelial function in streptozotocin-induced type I diabetes
[47], insulin-resistant type II diabetes [48], DOCA-salt induced
hypertension [49] and ischemia/reperfusion induced injury [50].
Figure 3. Representative Western blot (A) and densitometric quantification of phospho-p66Shc protein (B) expression in HAEC after
twenty-four hours of incubation with oxLDL in the presence of nitric oxide donor (DetaNO 0.1-1 mM or DeaNO 0.1–1 mM). The
phosphorylation of p66Shc was normalized to total p66Shc protein and total p66Shc was normalized to a-tubulin. Results are presented as
means6SEM; n = 5. * p,0.05 vs. cells under control conditions. # p,0.05 vs. oxLDL alone.
doi:10.1371/journal.pone.0107787.g003
eNOS and Oxidative Stress in Endothelial Cells
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Figure 4. Representive Western blot (A) and densitometric quantification of eNOS uncoupling (B) and phospho-p66Shc protein (C)
expression in HAEC after twenty-four hours incubation with oxLDL in the presence of tetrahydrobiopterin (BH4 10 mM), apocynin
(100 mM), bradykinin (1 mM) or calcium ionophore (A23187 1 mM). eNOS uncoupling was presented as ratio of dimer/monomer form of
eNOS. The phosphorylation of p66Shc was normalized to total p66Shc protein and total p66Shc was normalized to a-tubulin. Results are presented as
means6SEM; n = 8. * p,0.05 vs. cells under control conditions. # p,0.05 vs. oxLDL alone.
doi:10.1371/journal.pone.0107787.g004
eNOS and Oxidative Stress in Endothelial Cells
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Figure 5. Representive Western blot (A) and densitometric quantification of eNOS uncoupling (B) and phospho-p66Shc protein (C)
in HAEC after twenty-four hours incubation with oxLDL in the presence of tetrahydrobiopterin [BH4 10 mM; before (B), forty five
minutes after (After Early, AE), or sixteen hours after (After Later, AL) oxLDL treatment]. eNOS uncoupling was presented as ratio of
dimer/monomer form of eNOS. The phosphorylation of p66Shc was normalized to total p66Shc protein and total p66Shc was normalized to a-tubulin.
Results are presented as means6SEM; n = 8. * p,0.05 vs. cells treated with oxLDL alone.
doi:10.1371/journal.pone.0107787.g005
eNOS and Oxidative Stress in Endothelial Cells
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However, results in human studies are controversial; it has been
reported that tetrahydrobiopterin improves endothelial dysfunc-
tion in postmenopausal women [51], subjects with hypercholes-
terolemia [52], patients with chronic coronary disease [53],
smokers [54] and type II diabetic patients [55]. Additionally, it
was reported that oral tetrahydrobiopterin does not alter vascular
redox state or endothelial function owing to systemic and vascular
oxidation of tetrahydrobiopterin [56]. In the present study,
tetrahydrobiopterin treatment, prior to oxLDL stimulation,
prevented p66Shc-mediated oxidative stress, confirming that
tetrahydrobiopterin confers a protective effect on eNOS coupling.
Interestingly, this effect was also observed with tetrahydrobiopterin
treatment early after oxLDL stimulation, but not in the late
treatment, implying that other sources of oxidative stress
participate in ROS generation at late stage, which cannot be
inhibited by a late tetrahydrobiopterin treatment. p66Shc adaptor
protein is reported to translates oxidative damage into cell death
by acting as mediator of reactive oxygen species within
mitochondria [33]. We reported previously that upon oxLDL
stimulation in human aortic endothelial cells, p66Shc protein is
activated leading to increased p47phox protein expression and
superoxide anion production; this effect is mediated via lectin-like
oxLDL receptor-1, activation of protein kinase C beta-2 and c-Jun
N-terminal kinase, respectively [18]. Interestingly,, this effect could
not be prevented by p66Shc silencing. [18]. Thus the results in the
present study provide a possible molecular explanation for those
antioxidant treatments in large, long-term clinic trials, which have
failed to improve cardiovascular outcome [57,58,59].
The present experiments performed in cultured human primary
endothelial cells describe a dual role of eNOS for p66Shc protein
activation and reactive oxygen species generation. It appears that
eNOS uncoupling is a crucial player in oxLDL-induced and
p66Shc-mediated intracellular reactive oxygen species generation
(Figure 7). These findings provide important mechanistic infor-
mation about endothelial dysfunction, thus eNOS uncoupling
Figure 6. O2- production after twenty-four hours of incubation with oxLDL in the presence or absence of tetrahydrobiopterin [BH4
10 mM, before (B), forty five minutes after (AE), and sixteen hours after (AL) oxLDL treatment], apocynin (100 mM), bradykinin
(1 mM), calcium ionophore (1 mM), L-NAME (0.3 mM) and cGMP (1 mM). Results are presented as means6SEM; n = 8. * p,0.05 vs. cells under
control conditions. # p,0.05 vs. oxLDL alone.
doi:10.1371/journal.pone.0107787.g006
Figure 7. Putative role of eNOS in oxLDL-induced, p66Shc- mediated oxidative stress in HAEC. eNOS uncoupling is the primary source of
oxLDL-induced oxidative stress in endothelial cells, leading to the p66Shc activation and later surge of ROS production. Supply with nitric oxide or
reversal eNOS uncoupling reduces p66Shc activation and ROS production.
doi:10.1371/journal.pone.0107787.g007
eNOS and Oxidative Stress in Endothelial Cells
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represents a potential therapeutic target for early intervention of
atherosclerosis.
Supporting Information
Figure S1 Representative Western blot of eNOS, total Shc
protein (p66, p52, and p46), and a-tubulin expression in HAEC
treated with small interfering RNA against eNOS. (SiGAPDH:
small interfering RNA against GAPDH; NFS: nanoparticle
formation solution).
(EPS)
Figure S2 Representative Western blot (A) and densitometric
quantification of phospho-p66Shc protein expression (B) in HAEC
after twenty-four hours of incubation with oxLDL in the presence
of cGMP (1 mM) (A). The phosphorylation of p66Shc was
normalized to total p66Shc protein and total p66Shc was
normalized to a-tubulin. Results are presented as means6SEM;
n=5. * p,0.05 vs. cells under control conditions. # p,0.05 vs.
oxLDL alone.
(EPS)
Figure S3 Densitometric quantification of phospho-p66Shc
protein expression in HAEC after twenty-four hours of incubation
with oxLDL in the presence or absence of KT 5832 (1 mM). The
phosphorylation of p66Shc was normalized to total p66Shc protein
and total p66Shc was normalized to a-tubulin. Results are
presented as means6SEM; n= 5. * p,0.05 vs. cells under control
conditions.
(EPS)
Figure S4 Densitometric quantification of protein peroxynitri-
tion in HAEC after twenty-four hours of incubation with oxLDL.
The level of protein peroxynitrition was normalized to a-tubulin.
Results are presented as means6SEM; n= 5.
(EPS)
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